CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced the U.S. Food and Drug Administration (FDA) has authorized an expanded access ...

PARSIPPANY, N.J.--(BUSINESS WIRE)--Ferring Pharmaceuticals today announced the final 60-month follow-up data from the Phase 3 study of ADSTILADRIN ® (nadofaragene firadenovec-vncg) were presented at ...

Bladder instillations of bacillus Calmette-Guérin (BCG) in patients with nonmuscle-invasive bladder cancer (NMIBC) are associated with a decreased risk for Alzheimer disease and other dementias, ...

TARA-002 demonstrates high complete response rates in BCG-naïve NMIBC patients, with 72% achieving CR and 50% maintaining it at 12 months. The treatment involves six weekly bladder instillations, ...

In recent years the management of non-muscle-invasive bladder cancer has undergone radical changes. Intravesical Bacillus Calmette-Guérin (BCG) has long been established as the therapeutic standard ...

Bladder cancer is one of the more common cancers worldwide. It is considered a major health care problem with a high financial burden. Of these cases, 75% are non-muscle-invasive, which characterizes ...

A treatment combination of Anktiva and Bacillus Calmette-Guérin was approved by the FDA for certain patients with non-muscle-invasive bladder cancer. The Food and Drug Administration (FDA) has ...

SAN ANTONIO -- More than 70% of patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) achieved complete responses to a novel gene therapy, a small preliminary trial showed. Across ...

Nogapendekin alfa-inbakicept is now approved for the treatment of patients with BCG-unresponsive non-muscle invasive bladder cancer. The FDA has approved nogapendekin alfa-inbakicept (Anktiva) in ...

Allegheny Health Network Department of Urology is offering a gemcitabine intravesical system to provide the therapy for BCG-unresponsive NMIBC. Ongoing shortages of Bacillus Calmette-Guérin (BCG) and ...